ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3006

Activation of the Thromboxane A2 Receptor By 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma

Pei-Suen Tsou1, George Zakhem2, Beatrix Balogh2, M. Asif Amin3, Phillip Campbell4, Gautam Edhayan3, Ray A. Ohara3, Elena Schiopu3, Dinesh Khanna1, Alisa E. Koch2,5 and David A. Fox3, 1University of Michigan Scleroderma Program, Ann Arbor, MI, 2University of Michigan Medical School, Ann Arbor, MI, 3Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 5Department of Veteran's Affairs and University of Michigan, Ann Arbor, MI

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Angiogenesis and endothelial cells, Scleredema

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Scleroderma (SSc) is a complex disease characterized by inflammation, vasculopathy, and excessive deposition of extracellular matrix. Various studies have demonstrated a paradoxical increase in angiogenic mediators, such as vascular endothelial growth factor (VEGF), in both the skin and serum of patients with SSc. Despite this, angiogenesis does not occur normally. 8-isoprostane is an oxidized lipid created by excessive oxidative stress, and has been shown to be elevated in SSc. The thromboxane A2 receptor (TXAR) and ROCK pathway, which can be activated by 8-isoprostane (8-IP), inhibits VEGF-induced endothelial cell (EC) differentiation and migration. However, its role in SSc has not been examined. In this study we determined whether the TXAR pathway was activated by 8-IP in SSc ECs. Its effect on VEGF-induced angiogenesis was also determined.

Methods:

Dermal ECs were isolated from punch biopsies from healthy subjects or patients with diffuse cutaneous SSc. Angiogenesis was assessed by chemotaxis and in vitroMatrigel tube formation assays. TXAR expression was determined by qPCR and Western blotting. Knockdown studies were performed using TXAR siRNAs.

Results:

SSc patients had significantly higher 8-IP plasma levels (60.9±8.4 pg/ml) compared to healthy subjects (24.9±5.0 pg/ml, p<0.05). Increased oxidative stress was detected in SSc ECs as increased 8-IP in SSc EC conditioned media and excessive superoxide in SSc ECs were observed. In healthy ECs, 8-IP inhibited VEGF-induced EC migration, and the inactivation of TXAR or ROCK pathways restored VEGF-induced angiogenesis inhibited by 8-IP. In SSc ECs, VEGF did not induce EC migration, however, addition of the TXAR or ROCK inhibitors restored the pro-angiogenic effect of VEGF. This was further confirmed by TXAR siRNA experiments which showed that TXAR-knockdowned SSc ECs migrated towards VEGF while the SHAM-transfected ECs did not. We then measured ROCK activity in healthy and SSc ECs before and after VEGF or 8-IP stimulation. Basal ROCK activity was significantly higher in SSc ECs compared to healthy ECs. Moreover, 8-IP-induced ROCK activation was significantly higher in SSc ECs while VEGF induced significantly higher ROCK activation in healthy ECs. The expression of key players in this pathway was also examined. The protein expression of TXAR, RhoA, ROCK1/2 were all elevated in SSc ECs compared to healthy ECs.

Conclusion:

We show that 8-IP inhibits VEGF-induced migration in healthy ECs through the TXAR/ROCK pathway. ECs not only produce high levels of 8-IP, but also show elevated expression of TXAR and RhoA/ROCK levels. This could explain the increased activation of the TXAR pathway in terms of ROCK activity in SSc ECs compared to healthy ECs. This hyper-activation leads to inhibition of VEGF-induced EC migration, as using the TXAR or ROCK inhibitor, as well as specific knockdown of TXAR, results in restoration of VEGF activity. These results suggest that the TXAR pathway plays a crucial role in angiogenesis and that 8-IP is not just a by-product as a result of oxidative stress, but instead plays a significant role in impaired angiogenesis that characterizes SSc.


Disclosure:

P. S. Tsou,

University of Michigan Scleroderma Cure Fund,

9,

The Arthritis Foundation,

2;

G. Zakhem,
None;

B. Balogh,
None;

M. A. Amin,
None;

P. Campbell,
None;

G. Edhayan,
None;

R. A. Ohara,
None;

E. Schiopu,
None;

D. Khanna,

NIH K24 AR063120-02,

2,

University of Michigan Scleroderma Cure Fund,

9;

A. E. Koch,

Eli Lilly and Company,

3;

D. A. Fox,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activation-of-the-thromboxane-a2-receptor-by-8-isoprostane-inhibits-the-pro-angiogenic-effect-of-vascular-endothelial-growth-factor-in-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology